Protocols · Weight Management · Semaglutide
Research Protocol · Educational

Semaglutide
Dosage Protocol

How many syringe units is a given weekly dose from a 10 mg vial? Semaglutide is dosed once a week under the skin, and the reconstitution math, titration schedule, and unit conversions below answer that, with every figure sourced to the protocol guide and peer-reviewed literature cited.

Semaglutide
Semaglutide · 10 mg · research use only
Titration range
0.25–2.4 mg/week
Reconstitute
3.0 mL BAC water
Concentration
3.33 mg/mL
Storage
2–8 °C · ≤28 days
Dosage

Dosage Chart

Regulatory note. Semaglutide is FDA-approved under three brand names: Ozempic and Wegovy (subcutaneous injection, for type 2 diabetes and chronic weight management respectively) and Rybelsus (oral tablet, for type 2 diabetes). [1] The titration below is sourced to a research vial dosage protocol, not to a brand-name product insert; the escalation pattern (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly) matches the publicly known dose steps used in the approved injectable label, but this page is not the approved product and does not substitute for its prescribing information. The FDA has separately warned against unapproved, compounded semaglutide products and reported dosing errors in compounded formulations. [1]

Graduated weekly subcutaneous dosing for the 10 mg vial, escalating every 4 weeks. [4]

PhaseWeekly doseUnits (U-100)Volume
Weeks 1–4250 mcg7.5 u0.075 mL
Weeks 5–8500 mcg15 u0.15 mL
Weeks 9–121,000 mcg30 u0.30 mL
Weeks 13–161,700 mcg51 u0.51 mL
Weeks 17+ (maintenance)2,400 mcg72 u0.72 mL

Protocols run 16–20+ weeks with gradual escalation every 4 weeks until the maintenance dose is reached. [4] Oral semaglutide (Rybelsus) is a distinct daily formulation with its own administration requirements and is not covered by this injectable vial protocol. [1]

Prep

Reconstitution

10 mg vial, mixed to a working concentration before drawing a dose.

Add 3.0 mL of bacteriostatic water to the 10 mg vial to yield a final concentration of approximately 3.33 mg/mL. Inject the water slowly down the vial wall to minimize foaming; avoid shaking, and gently swirl or roll the vial until fully dissolved. [4]

Store the lyophilized vial at −20 °C. Once reconstituted, store at 2–8 °C, protected from light, and use within 28 days. [4]

Mechanism

How It Works

Semaglutide is a synthetic GLP-1 receptor agonist containing 31 amino acids, with molecular modifications at position 8 and a C18 fatty-diacid attached at position 26 that binds albumin. This albumin-binding modification extends the half-life to approximately 160 hours, enabling once-weekly dosing. [5][2]

In the STEP-HFpEF trial, 529 patients with heart failure with preserved ejection fraction and obesity received once-weekly semaglutide (2.4 mg) or placebo over 52 weeks; semaglutide produced larger reductions in symptoms and physical limitations, plus greater improvements in exercise function. It also produced greater weight loss, with serious adverse events reported in 13.3% of the semaglutide group versus 26.7% of the placebo group. [3] Semaglutide's clinical development spans the SUSTAIN program (diabetes) and STEP program (obesity) through Phase I–III trials, with post-marketing surveillance continuing through 2025. [2]

Semaglutide carries a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. [1] Common adverse effects include nausea, vomiting, diarrhea, and constipation; serious risks include acute pancreatitis, gallbladder disease, and acute kidney injury. [1] This section describes what the cited literature reports; it is not a claim of safety or effectiveness beyond the approved indications.

Evidence

References

[1] Semaglutide overview · PeptideDosages

[2] Semaglutide from Bench to Bedside · Weiskirchen & Lonardo, 2025, PMID 41283266

[3] Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Obesity · STEP-HFpEF, NEJM, 2023, PMID 37622681

[4] Semaglutide 10 mg vial dosage protocol · PeptideDosages

[5] FDA NDA 213051 Chemistry Review (Ozempic) · FDA

Educational use only. This content is for research and educational purposes only and is not medical advice, diagnosis, or treatment. FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription medication requiring physician oversight; this page describes a research vial protocol, not the approved brand product. It is not intended for human consumption outside a prescribed, approved use. Clinical decisions should involve a qualified healthcare provider.